Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises 1Vision Biogas on its public offer for Biokraft
Mandate

Vinge advises 1Vision Biogas on its public offer for Biokraft

February 05, 2024 Capital Markets and Public M&A M&A FDI EU, Competition and Regulatory

1Vision Biogas AB, a company controlled by Aneo, HitecVision and St1, has made a public mandatory bid for all shares in Biokraft International AB. The offer values the shares of Biokraft at approximately SEK 900 million. Vinge advises 1Vision Biogas.

The Vinge team includes Christian Lindhé, Erik Sjöman, Martin Madsen Svanberg, Johan Åhman and Johan Severinsson (Capital Markets and Public M&A), Jesper Ottergren (M&A) as well as Sofie Nordgren, Pär Remnelid, Rikard Azelius and Jasmine Elgh (FDI/EU, Competition and Regulatory).

Related

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

 Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.
October 22, 2024

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its directed share issue

 Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore receives issue proceeds of approximately SEK 100 million before deduction of transaction costs.
October 22, 2024

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS

 Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS. The proceedings, which included considerations regarding state aid approved by the European Commission, have among other things involved restructuring, debt write-downs as well as an investment by a consortium consisting of Castlelake, Air France-KLM, Lind Invest and the Danish state. In total, the investment amounted to approximately USD 1.2 billion in SAS, divided into USD 475 million in unlisted equity and USD 725 million in convertible debt.
October 21, 2024